NASDAQ:ARDX - Ardelyx Stock Price, Forecast & News

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Ardelyx Inc (NASDAQ:ARDX) issued its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, meeting the consensus estimate of ($0.37). The biopharmaceutical company had revenue of $3.01 million for the quarter. View Ardelyx's Earnings History.

Ardelyx is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Ardelyx.

6 brokerages have issued twelve-month price objectives for Ardelyx's stock. Their forecasts range from $9.00 to $15.00. On average, they expect Ardelyx's share price to reach $11.40 in the next year. This suggests a possible upside of 58.3% from the stock's current price. View Analyst Price Targets for Ardelyx.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ardelyx.

Media headlines about ARDX stock have been trending neutral this week, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ardelyx earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Ardelyx.

Ardelyx saw a increase in short interest in January. As of January 15th, there was short interest totalling 3,940,000 shares, an increase of 42.8% from the December 31st total of 2,760,000 shares. Based on an average trading volume of 890,800 shares, the short-interest ratio is currently 4.4 days. Currently, 6.3% of the shares of the company are short sold. View Ardelyx's Current Options Chain.

Some companies that are related to Ardelyx include Arvinas (ARVN), Alder Biopharmaceuticals (ALDR), Amneal Pharmaceuticals (AMRX), BELLUS Health (BLUSF), Athenex (ATNX), Endonovo Therapeutics (ENDV), Applied Therapeutics (APLT), I-Mab (ARQT), Achillion Pharmaceuticals (ACHN), Amphastar Pharmaceuticals (AMPH), Dova Pharmaceuticals (DOVA), ANI Pharmaceuticals (ANIP), CannTrust (CNTTF), DiaMedica Therapeutics (DMCAF) and Aprea Therapeutics (APRE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX), BioCryst Pharmaceuticals (BCRX), ImmunoGen (IMGN), Idera Pharmaceuticals (IDRA), SCYNEXIS (SCYX) and Synergy Pharmaceuticals (SGYP).

Ardelyx's stock is owned by a variety of of institutional and retail investors. Top institutional investors include NEA Management Company LLC (24.52%), RA Capital Management L.P. (8.14%), Renaissance Technologies LLC (3.74%), Marshall Wace LLP (1.74%), State Street Corp (1.35%) and Ikarian Capital LLC (0.98%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Gordon Ringold, Mark Kaufmann, Michael Raab and Scott D Sandell. View Institutional Ownership Trends for Ardelyx.

ARDX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Jacobs Levy Equity Management Inc., Tower Research Capital LLC TRC , Blair William & Co. IL and Citigroup Inc.. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Mark Kaufmann and Michael Raab. View Insider Buying and Selling for Ardelyx.

ARDX stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Marshall Wace LLP, NEA Management Company LLC, Ikarian Capital LLC, J. Goldman & Co LP, Bailard Inc., FMR LLC and Goldman Sachs Group Inc.. View Insider Buying and Selling for Ardelyx.

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ARDX stock can currently be purchased for approximately $7.20.

Ardelyx has a market capitalization of $473.76 million and generates $2.61 million in revenue each year. The biopharmaceutical company earns $-91,300,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Ardelyx employs 86 workers across the globe.View Additional Information About Ardelyx.